83 related articles for article (PubMed ID: 34230142)
1. IL13 Fused
Uludağ D; Karakaş N
Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
[TBL] [Abstract][Full Text] [Related]
2. Engineering toxin-resistant therapeutic stem cells to treat brain tumors.
Stuckey DW; Hingtgen SD; Karakas N; Rich BE; Shah K
Stem Cells; 2015 Feb; 33(2):589-600. PubMed ID: 25346520
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.
Rosada RS; Moreira AP; Frantz FG; Puri RK; Rahman A; Standiford TJ; Zárate-Bladés CR; Silva CL; Hogaboam CM
PLoS One; 2010 Jan; 5(1):e8721. PubMed ID: 20090941
[TBL] [Abstract][Full Text] [Related]
4. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
5. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
7. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
8. Increasing stability and toxicity of Pseudomonas exotoxin by attaching an antiproteasic Peptide.
Méré J; Chopard C; Bonhoure A; Morlon-Guyot J; Beaumelle B
Biochemistry; 2011 Nov; 50(46):10052-60. PubMed ID: 22014283
[TBL] [Abstract][Full Text] [Related]
9. IL13Rα2‑ and EGFR‑targeted pseudomonas exotoxin potentiates the TRAIL‑mediated death of GBM cells.
Karakaş N; Stuckey D; Revai-Lechtich E; Shah K
Int J Mol Med; 2021 Jul; 48(1):. PubMed ID: 34080646
[TBL] [Abstract][Full Text] [Related]
10. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.
Husain SR; Obiri NI; Gill P; Zheng T; Pastan I; Debinski W; Puri RK
Clin Cancer Res; 1997 Feb; 3(2):151-6. PubMed ID: 9815666
[TBL] [Abstract][Full Text] [Related]
11. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
12. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
13. A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.
Sato Y; Vatsan R; Joshi BH; Husain SR; Puri RK
Curr Mol Med; 2023 Mar; ():. PubMed ID: 36999709
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture.
Zhu Y; Weldon JE
BMC Res Notes; 2019 May; 12(1):293. PubMed ID: 31133049
[TBL] [Abstract][Full Text] [Related]
15. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
Debinski W; Obiri NI; Pastan I; Puri RK
J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490
[TBL] [Abstract][Full Text] [Related]
16. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications.
Wu T; Zhu J
Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138
[TBL] [Abstract][Full Text] [Related]
17. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
Gholipour Z; Fooladi AAI; Parivar K; Halabian R
Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
19. Heparin-binding transforming growth factor alpha-Pseudomonas exotoxin A. A heparan sulfate-modulated recombinant toxin cytotoxic to cancer cells and proliferating smooth muscle cells.
Mesri EA; Kreitman RJ; Fu YM; Epstein SE; Pastan I
J Biol Chem; 1993 Mar; 268(7):4853-62. PubMed ID: 8444864
[TBL] [Abstract][Full Text] [Related]
20. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
